abrdn World Healthcare Fund Q1 2025 Commentary
Source: SeekingAlpha
2025-06-03 08:20:00 ET
Summary
- The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter.
- The top three detractors over the quarter were Novo Nordisk, uniQure and Teva Pharmaceutical Industries.
- The top three positive contributors were Roche Holding, AbbVie and AstraZeneca.
Fund performance
Read the full article on Seeking Alpha
For further details see:
abrdn World Healthcare Fund Q1 2025 Commentary
Aberdeen Australia Equity Fund Inc
NASDAQ: IAF
IAF Trading
-1.77% G/L:
$12.80 Last:
17,553 Volume:
$12.88 Open:
IAF Latest News
February 10, 2026 04:17:00 pm
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
October 08, 2025 04:17:00 pm
ABRDN AUSTRALIA EQUITY FUND, INC. ANNOUNCES DETAILS OF UPCOMING 1-FOR-3 REVERSE STOCK SPLIT
